Resources Case Studies Coding & Billing Implementation Tools Package Inserts Product Information Videos, Webinars, & Podcasts Select ProductAll ProductsIFCPlasmaPlateletsPRPCRSelect Resource TypeAll Resource TypesCase StudiesCoding & BillingImplementation ToolsPackage InsertsProduct InformationVideos, Webinars, & PodcastsUINTERCEPT Goes Beyond – Platelets and IFCINTERCEPT Fibrinogen Complex (IFC)INTERCEPT Blood System for PlateletsINTERCEPT Blood System Mechanism of ActionAssessing Impact of IFC on Wastage and MTPsImplementing the Use of IFC in Pediatric SettingAssessing Platelet Availability – PR vs. LVDSUse of PR Platelets for Patient Safety and SustainabilityImplementation of PR at Puerto Rico Blood Center During Zika OutbreakOptimizing Platelet Availability and Access to 100% PR InventoryVersiti PR Scale-UpUS Tertiary Care Hospital Gains Operational Efficiency and Fresher PlateletsStanford Blood Center Implements 100% PRImplementation of INTERCEPT Fibrinogen Complex (IFC) at Stanford HospitalISBT Platelets CodesPlatelets and Plasma Outpatient Information GuideIFC Medicare Coding and Payment GuideIFC and PRPCR Coding InformationSample Labels SheetSample SBAR SheetPR Platelets Implementation GuideSample Tie Tags SheetImplementing INTERCEPT Platelets – E-learning TestBest Practices Platelet Handling Guide – HospitalsNurse Training ModuleNurse Handout TemplatePlatelets Small Volume (SV) Semi-Integrated Set – INT2140BPlasma (P) Semi-Integrated Set – INT3140BPlasma (P) – INT3130Platelets Large Volume (LV) – INT2230BPlatelets Dual Storage (DS) – INT2530BPlatelets Large Volume (LV) Semi-Integrated Set – INT2240BPlatelets Small Volume (SV) – INT2130BPlatelets Dual Storage (DS) Semi-Integrated Set – INT2540BPathogen Reduced Plasma, Cryoprecipitate Reduced – PRPCRPathogen Reduced Cryoprecipitated Fibrinogen Complex – IFCINTERCEPT Plasma Specifications InsertCMV Mitigation SheetINTERCEPT Platelets Interview: Dr. Maria De Los Angeles Muñiz – Robert Wood Johnson University HospitalPR – Proactive Strategy for Blood Safety in Pandemic PreparationMethodologies for Reducing the Risk of TA-GVHD from Platelet TransfusionsINTERCEPT Integrated Sets Specifications InsertPlatelets Safety and Efficacy Technical SheetINTERCEPT Platelets Interview: Dr. Deva Sharma – Vanderbilt University Medical CenterINTERCEPT Platelets Interview: Dr. Shannon Walker – Vanderbilt University Medical CenterINTERCEPT Semi-integrated Sets Specifications InsertPlasma Safety and Efficacy Technical SheetPathogen Reduced Plasma, Cryoprecipitate Reduced (PRPCR)Impact of PR vs LVDS Testing on Platelet AvailabilitySafety and Efficacy of Amotosalen-UVA PR Platelet Components Transfused to Mature and Premature Neonates – Cerus CorporationImplementation & Quality Analysis of Pathogen Reduced Cryoprecipitated Fibrinogen Complex – Stanford UniversityImplementation of Pathogen Reduced Cryoprecipitated Fibrinogen Complex in a Pediatric Level II Trauma Center – Valley Children’s HealthcareImproved Operational Efficiencies With Pathogen Reduced Cryoprecipitated Fibrinogen Complex vs. CryoAHF – UTSW Medical CenterReduced Blood Bank Product Preparation Time and Waste with Implementation of Pathogen Reduced Cryoprecipitate – Kaiser PermanenteComparing Useable Shelf-life of PR Platelets vs LVDS Screened Platelets – OneBloodPlatelets Economic Model – RutgersPhased Implementation of Pathogen-Reduced Platelets – UCSDLogistical Management of Incorporating Pathogen Reduced Platelets into Inventory – Yale New-Haven HospitalThe Effects of PAS and PR on Platelet Use – Roswell Park Cancer InstituteImpact of Amotosalen/UVA Process for PR in PLT Concentrates on Transfusion Efficiency in Cardiac Surgery – Saint-Etienne, FranceINTERCEPT Platelets Publications List2022 AABB Abstract Book2023 AABB Abstract BookSeptic Transfusion Reaction AwarenessFibrinogen Supplementation in Hemorrhagic Shock: Role of INTERCEPT® Fibrinogen ComplexPathogen Reduced Cryoprecipitated Fibrinogen Complex (INTERCEPT® Fibrinogen Complex or IFC) and INTERCEPT® treated Platelets: Expanding the Use of Pathogen Reduction for Improved Blood SafetyMerits and Pitfalls of Automated Bacterial Culture Methods in Improving Bacterial Safety of Platelet ConcentratesImplementing Pathogen Reduced Platelets: A TSO (Transfusion Safety Officer) Perspective (Allegheny Health Network)Implementing Pathogen Reduced Platelets: A TSO (Transfusion Safety Officer) Perspective (Johns Hopkins All Children’s Hospital)Impact of Platelet Transfusion on Pulmonary Function of Hematology Oncology Patients: The PIPER StudyImpact of Anaerobic Culture of Platelets on Safety and OperationsThe Rationale for Pathogen Reduction: Blood Center and Transfusion Services PerspectivesPlatelet Pathogen Reduction Technology Implementation at Stanford Blood CenterPathogen Reduced Platelet Implementation at Stanford HospitalHemostatic Efficacy of Pathogen Reduced Platelets in Pediatric Cardiopulmonary BypassReview of Neonate to Pediatric Patient Outcomes Transfused with Amotosalen/UVA Treated PlateletsAssessing Platelet Availability from Blood Center and Hospital PerspectivesEvaluating Usable Shelf-Life of Pathogen Reduced and LVDS Tested Platelet ComponentsPathogen Reduction of Platelets: Patient Safety and FDA Platelet Bacterial Guidance CompliancePathogen Reduction of Platelets: Guidance Compliance and ImplementationPreparing Our Blood Supply for the Next Pandemic with Dr. Susan StramerUpdating a Software Model to Estimate the Cost and Shelf Life Implications of New Platelet TechnologiesImplementing Pathogen Reduced (PR) INTERCEPT Platelets and Pediatric ConsiderationsPlatelet Component Bacterial Risk Control: An Evolution in ProgressImplementing the Use of INTERCEPT® Fibrinogen Complex (IFC) in the Pediatric SettingINTERCEPT Fibrinogen Complex: Implementation and Initial ExperiencePostpartum Hemorrhage and Target-Directed MTP Lessons-Learned about Fibrinogen ReplacementUF Health Shands’ Experience to Date with INTERCEPT® Fibrinogen Complex (IFC)Introducing a new cryoprecipitated coagulopathy treatment: INTERCEPT® Fibrinogen ComplexMeeting the Ever-changing Needs of Pediatric MTPINTERCEPT® Fibrinogen Complex in Cardiac Surgery: Experience at StanfordINTERCEPT Fibrinogen Complex: Initial Experience at UF Health
INTERCEPT Platelets Interview: Dr. Maria De Los Angeles Muñiz – Robert Wood Johnson University Hospital
Safety and Efficacy of Amotosalen-UVA PR Platelet Components Transfused to Mature and Premature Neonates – Cerus Corporation
Implementation & Quality Analysis of Pathogen Reduced Cryoprecipitated Fibrinogen Complex – Stanford University
Implementation of Pathogen Reduced Cryoprecipitated Fibrinogen Complex in a Pediatric Level II Trauma Center – Valley Children’s Healthcare
Improved Operational Efficiencies With Pathogen Reduced Cryoprecipitated Fibrinogen Complex vs. CryoAHF – UTSW Medical Center
Reduced Blood Bank Product Preparation Time and Waste with Implementation of Pathogen Reduced Cryoprecipitate – Kaiser Permanente
Logistical Management of Incorporating Pathogen Reduced Platelets into Inventory – Yale New-Haven Hospital
Impact of Amotosalen/UVA Process for PR in PLT Concentrates on Transfusion Efficiency in Cardiac Surgery – Saint-Etienne, France
Pathogen Reduced Cryoprecipitated Fibrinogen Complex (INTERCEPT® Fibrinogen Complex or IFC) and INTERCEPT® treated Platelets: Expanding the Use of Pathogen Reduction for Improved Blood Safety
Merits and Pitfalls of Automated Bacterial Culture Methods in Improving Bacterial Safety of Platelet Concentrates
Implementing Pathogen Reduced Platelets: A TSO (Transfusion Safety Officer) Perspective (Allegheny Health Network)
Implementing Pathogen Reduced Platelets: A TSO (Transfusion Safety Officer) Perspective (Johns Hopkins All Children’s Hospital)
Impact of Platelet Transfusion on Pulmonary Function of Hematology Oncology Patients: The PIPER Study
Updating a Software Model to Estimate the Cost and Shelf Life Implications of New Platelet Technologies